ESTA Establishment Labs Holdings

Establishment Labs to Announce First Quarter 2020 Financial Results on May 7

Establishment Labs to Announce First Quarter 2020 Financial Results on May 7

NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (Nasdaq: ESTA), a medical technology company focused on Women’s Health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended March 31, 2020 after the market closes on Thursday, May 7, 2020, and will host a conference call at 5:00 pm ET that day to discuss those results.

To participate in the conference call, dial (877) 376-9925 (U.S. and Canada) or (629) 228-0732 (International) and use conference ID number 4586958. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at .

About Establishment Labs

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information: 

Investor/Media Contact:
David K. Erickson
Establishment Labs Holdings Inc.
949-447-6671
 
EN
23/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Establishment Labs Holdings

 PRESS RELEASE

Establishment Labs Notes Presentation of 5-Year Results from Motiva U....

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include five-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the results at The Aesthetic MEET 2025, the annual meeting of The Aesthetic Society, in Austin, Texas. Dr...

 PRESS RELEASE

Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial...

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2024 and reaffirmed 2025 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $44.5 million, consistent with preannouncement on January 13. Motiva Implants approved and launched in U.S.; Motiva U.S. revenue in the fourth quarter of $3.3 million. Fourth quarter...

 PRESS RELEASE

Establishment Labs to Present at TD Cowen's 45th Annual Health Care Co...

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in TD Cowen's 45th Annual Health Care Conference. Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Tuesday, March 4, 2025 at 2:30 p.m. ET. A live webcast of the presentation will be available on the Establishment Labs investor relations websit...

 PRESS RELEASE

Establishment Labs to Present at Citi’s 2025 Unplugged Medtech and Lif...

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in a fireside chat at Citi's 2025 Unplugged Medtech and Life Sciences Access Day. Juan José Chacón-Quirós, Chief Executive Officer and Founder; Peter Caldini, President; and Raj Denhoy, Chief Financial Officer, are scheduled to present on Thursday, February 27, 2025 at 8:00 a.m. ET. A live webcast of the presentation will be available on the Es...

 PRESS RELEASE

Establishment Labs Launches Preservé™

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction, announced it has launched Preservé™ in Brazil, the first country in its global rollout. Preservé is the second product in the Company’s minimally invasive platform, building upon the technologies and techniques developed with Mia Femtech®, Establishment Labs’ minimally invasive experience. “These are not small innovations, this is an entirely new era for aesthetic breast surgery,” said Juan ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch